Quest Diagnostics Announces Planned Retirement and Role Transition for EVP Catherine T. Doherty

Executive Transition Summary

On October 6, 2026, Quest Diagnostics Incorporated filed a Form 8-K under Item 5.02 disclosing an executive transition and planned retirement for Catherine T. Doherty.

Key Details:

• Retirement Timeline: Ms. Doherty will retire from the company in July 2027.
• Interim Role: Effective November 1, 2026, Ms. Doherty will transition to an Executive Vice President role focusing on:
  • Health systems partnerships
  • The joint venture with Corewell Health
  • Project Nova (the multi-year initiative modernizing 'Order to Cash' business processes, IT infrastructure, and enabling technologies)

Compensation & Equity Arrangements:

• Base Salary: Maintained with no change at $650,000 annually.
• Annual Incentive Plan: Maintained under the Senior Management Incentive Plan at a target level of 80% of base salary ($520,000 target).
• Long-Term Incentive Award: Approved by the Compensation and Leadership Development Committee for a grant date of November 3, 2026, with a target value of $1,200,000 allocated 100% to restricted stock units (RSUs).

Market Impact & Governance Implications:

The disclosure reflects a planned, orderly leadership transition over a nine-month horizon leading to retirement in July 2027. It carries low trading significance for equity investors.